Noda.My understanding is that Acadia is committed to do the Phase 3 trials of trofinetide for both retts and fragile X so the money they are investing say $180 mill is substantially more than our capitalisation of $120 million and Neuren still owns the row rights for trofinetide and NNZ2591 .At the end of December they had about $660 mill aussie in the bank so funding should not be a problem .This is just a waiting game until the market wakes up to its potential.
Current Stock Valuation ., page-108
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.06 |
Change
-0.330(1.70%) |
Mkt cap ! $2.440B | |||
| Open | High | Low | Value | Volume |
| $19.55 | $19.65 | $18.88 | $1.894M | 98.91K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 256 | $19.05 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.06 | 393 | 1 |
View Market Depth
| Last trade - 10.50am 31/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |